MDCX (medicuspharma.com) Rasio Nilai Pasar marang Nilai Buku

Simbol resmi perusahaan Medicus Pharma Ltd (MDCX)

The asset value of Medicus Pharma Ltd. (MDCX), currently -2.42 as shown on the chart, demonstrates the business's resilience to global crises due to the specific nature of medical cycles. Medicus Pharma Ltd. (MDCX) develops innovative patches to combat skin oncology, leveraging unique patents to protect against price wars. The company's success relies on clinical trial results and regulatory approvals in its competition with traditional surgery.

MDCX Medicus Pharma Corp: Nilai Pasar marang Nilai Buku ing interval 15.11.2024 - 28.10.2026

Rincian metrik keuangan lan pasar Medicus Pharma Ltd (MDCX)

- rega lan prakiraan konsensus rega:
Kutipan saham Medicus Pharma Ltd.|MDCX - Prakiraan gabungan firma investasi
- data kapitalisasi pasar:
Nilai pasar Medicus Pharma Limited|MDCX - Nilai Wutuh Bisnis
- data kapitalisasi buku:
Nilai Buku saben Saham Medicus Pharma|MDCX - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku medicuspharma.com|MDCX - Total Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas Medicus Pharma Ltd.|MDCX - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Medicus Pharma Limited|MDCX - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Medicus Pharma Limited
Analisis wiwitan perusahaan:Medicus Pharma Ltd. - MDCX
Produk asli Medicus Pharma Limited

Investors are assessing the stability of Medicus Pharma Ltd. (MDCX) through the lens of its reliance on external financing for clinical development. The absence of operational cash flow renders the company's assets a pledge for its future. This metric compares the business's market value with its net book assets to determine the expectation premium. By analyzing the change in the market cap to book capitalization ratio on GURU.Markets, one can evaluate the efficiency of capital management. This trend serves as an indicator of market confidence in the commercialization of the company's drugs.

Pesaing utama

Rasio Kapitalisasi marang Aset Bersih Krystal Biotech, Inc.|APGE (apogeetherapeutics.com) - Rasio Kapitalisasi marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Arcutis Biotherapeutics, Inc. ARQT|Kapitalisasi Pasar marang Aset Bersih Vericel Corp|Oruka Corp (ORKA) - Rasio Kapitalisasi Pasar marang Nilai Buku|Nilai Pasar marang Nilai Buku sanaramedtech.com (SMTI)|Rasio Kapitalisasi Pasar marang Nilai Buku DBVT (DBV Technologies)|Solesence Beauty - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Journey Medical Corp. (DERM)|FBRX: Nilai Pasar marang Nilai Buku|EMPG (Empro) - Rasio Nilai Pasar marang Nilai Buku|Sol-Gel Technologies, Ltd. (SLGL) - Rasio Kapitalisasi marang Aset Bersih|AXIL (AXIL Brands Inc) - Rasio Kapitalisasi Pasar marang Nilai Buku|Rasio Kapitalisasi Pasar marang Nilai Buku Verrica (VRCA)|Hoth Therapeutics, Inc. (HOTH) - Rasio Kapitalisasi marang Aset Bersih|Nilai Pasar marang Nilai Buku BFRI (biofrontera-us.com)|Rasio Nilai Pasar marang Nilai Buku VYNE|Sonoma Pharmaceuticals Inc. - Kapitalisasi Pasar marang Nilai Buku|Quoin Pharma - Rasio Nilai Pasar marang Nilai Buku|AZTR - Rasio Kapitalisasi Pasar marang Nilai Buku|Dermata Therapeutics, Inc. - Rasio Kapitalisasi Pasar marang Nilai Buku|ELAB (Elevai Labs Inc) - Kapitalisasi Pasar marang Nilai Buku|Rasio Nilai Pasar marang Nilai Buku Revance Therapeutics, Inc (RVNC)